News

BioSpace1d
Sage’s Story Comes to ‘Good End’ With Up To $795M Acquisition by Supernus
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
Sage Therapeutics shares gained 0.4% to trade at $9.11 on Tuesday. These analysts made changes to their price targets on Sage ...
Fierce Pharma1d
Supernus acquires struggling Sage for $561M, taking a flier on postpartum depression drug Zurzuvae
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...
Sage, following Setbacks, to sell to Supernus for $561M
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE ...
pharmaphorum1d
After rebuffing Biogen, Sage pairs off with Supernus
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
TMCnet1d
Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The transaction agreement unreasonably limits competing transactions for Sage by imposing a significant penalty if Sage accepts a competing bid. We are investigating the conduct of the Sage board of ...